{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:45:55Z","timestamp":1794051955576,"version":"4.8.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CAN-SOLVE-CKD SCA-145103"],"award-info":[{"award-number":["CAN-SOLVE-CKD SCA-145103"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Using age- and height-adjusted total kidney volume, the Mayo Clinic Imaging Classification provides a validated approach to assess the risk of chronic kidney disease (CKD) progression in autosomal dominant polycystic kidney disease (ADPKD), but requires excluding patients with atypical imaging patterns, whose clinical characteristics have been poorly defined. We report an analysis of the prevalence, clinical and genetic characteristics of patients with atypical polycystic kidney disease by imaging. Patients from the extended Toronto Genetic Epidemiology Study of Polycystic Kidney Disease recruited between 2016 and 2018 completed a standardized clinical questionnaire, kidney function assessment, genetic testing, and kidney imaging by magnetic resonance or computed tomography. We compared the prevalence, clinical features, genetics, and renal prognosis of atypical versus typical polycystic kidney disease by imaging. Forty-six of the 523 (8.8%) patients displayed atypical polycystic kidney disease by imaging; they were older (55 vs. 43\u00a0years;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001), and less likely to have a family history of ADPKD (26.1% vs. 74.6%;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001), a detectable\n                    <jats:italic>PKD1<\/jats:italic>\n                    or\n                    <jats:italic>PKD2<\/jats:italic>\n                    mutation (9.2% vs. 80.4%;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001), or progression to CKD stage 3 or stage 5 (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). Patients with atypical polycystic kidney disease by imaging represent a distinct prognostic group with a low likelihood of progression to CKD.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-24104-w","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T07:04:35Z","timestamp":1676876675000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Atypical Polycystic Kidney Disease as defined by Imaging"],"prefix":"10.1038","volume":"13","author":[{"given":"Ioan-Andrei","family":"Iliuta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung Zaw","family":"Win","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Lanktree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Heyck","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Pourafkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Nasri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Guiard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirreza","family":"Haghighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Quist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korosh","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"York","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"24104_CR1","first-page":"1356","volume":"32","author":"CJ Willey","year":"2017","unstructured":"Willey, C. J. et al. Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol. Dial. Transpl. 32, 1356\u20131363 (2017).","journal-title":"Nephrol. Dial. Transpl."},{"key":"24104_CR2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018050493","author":"MB Lanktree","year":"2018","unstructured":"Lanktree, M. B. et al. Prevalence estimates of polycystic kidney and liver disease by population sequencing. J. Am. Soc. Nephrol. https:\/\/doi.org\/10.1681\/ASN.2018050493 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"24104_CR3","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05900519","author":"T Suwabe","year":"2019","unstructured":"Suwabe, T. et al. Epidemiology of autosomal dominant polycystic kidney disease in Olmsted County. Clin. J. Am. Soc. Nephrol. https:\/\/doi.org\/10.2215\/CJN.05900519 (2019).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"24104_CR4","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","volume":"393","author":"E Cornec-Le Gall","year":"2019","unstructured":"Cornec-Le Gall, E., Alam, A. & Perrone, R. D. Autosomal dominant polycystic kidney disease. Lancet 393, 919\u2013935 (2019).","journal-title":"Lancet"},{"key":"24104_CR5","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407\u20132418 (2012).","journal-title":"N. Engl. J. Med."},{"key":"24104_CR6","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres, V. E. et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N. Engl. J. Med. 377, 1930\u20131942 (2017).","journal-title":"N. Engl. J. Med."},{"key":"24104_CR7","doi-asserted-by":"publisher","first-page":"205435811880158","DOI":"10.1177\/2054358118801589","volume":"5","author":"S Soroka","year":"2018","unstructured":"Soroka, S. et al. Updated Canadian expert consensus on assessing risk of disease progression and pharmacological management of autosomal dominant polycystic kidney disease. Can. J. Kidney Health Dis. 5, 2054358118801589 (2018).","journal-title":"Can. J. Kidney Health Dis."},{"key":"24104_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ndt\/gfv456","volume":"31","author":"RT Gansevoort","year":"2016","unstructured":"Gansevoort, R. T. et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: A position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol. Dial. Transpl. 31, 337\u2013348 (2016).","journal-title":"Nephrol. Dial. Transpl."},{"key":"24104_CR9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.kint.2017.09.027","volume":"93","author":"ASL Yu","year":"2018","unstructured":"Yu, A. S. L. et al. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in autosomal dominant polycystic kidney disease. Kidney Int. 93, 691\u2013699 (2018).","journal-title":"Kidney Int."},{"key":"24104_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal, M. V. et al. Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials. J. Am. Soc. Nephrol. 26, 160\u2013172 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"24104_CR11","first-page":"1857","volume":"32","author":"MV Irazabal","year":"2017","unstructured":"Irazabal, M. V. et al. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: The HALT-PKD clinical trial. Nephrol. Dial. Transpl. 32, 1857\u20131865 (2017).","journal-title":"Nephrol. Dial. Transpl."},{"key":"24104_CR12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ekir.2017.02.011","volume":"2","author":"RD Perrone","year":"2017","unstructured":"Perrone, R. D. et al. A drug development tool for trial enrichment in patients with autosomal dominant polycystic kidney disease. Kidney Int. Rep. 2, 451\u2013460 (2017).","journal-title":"Kidney Int. Rep."},{"key":"24104_CR13","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1681\/ASN.2018060590","volume":"29","author":"FT Chebib","year":"2018","unstructured":"Chebib, F. T. et al. A practical guide for treatment of rapidly progressive ADPKD with Tolvaptan. J. Am. Soc. Nephrol. 29, 2458\u20132470 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"24104_CR14","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02320220","author":"MB Lanktree","year":"2020","unstructured":"Lanktree, M. B., Haghighi, A., di Bari, I., Song, X. & Pei, Y. Insights into autosomal dominant polycystic kidney disease from genetic studies. Clin. J. Am. Soc. Nephrol. https:\/\/doi.org\/10.2215\/CJN.02320220 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"24104_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.08.038","author":"K Hopp","year":"2019","unstructured":"Hopp, K. et al. Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2019.08.038 (2019).","journal-title":"Kidney Int."},{"key":"24104_CR16","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3390\/genes5041064","volume":"5","author":"D Freed","year":"2014","unstructured":"Freed, D., Stevens, E. L. & Pevsner, J. Somatic mosaicism in the human genome. Genes 5, 1064\u20131094 (2014).","journal-title":"Genes"},{"key":"24104_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0168-9525(00)02178-8","volume":"17","author":"B Gottlieb","year":"2001","unstructured":"Gottlieb, B., Beitel, L. K. & Trifiro, M. A. Somatic mosaicism and variable expressivity. Trends Genet. 17, 79\u201382 (2001).","journal-title":"Trends Genet."},{"key":"24104_CR18","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1681\/ASN.2016090938","volume":"28","author":"I-A Iliuta","year":"2017","unstructured":"Iliuta, I.-A. et al. Polycystic kidney disease without an apparent family history. J. Am. Soc. Nephrol. 28, 2768\u20132776 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"24104_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.kint.2019.11.019","volume":"97","author":"O Devuyst","year":"2020","unstructured":"Devuyst, O. & Pei, Y. Next-generation sequencing for detection of somatic mosaicism in autosomal dominant polycystic kidney disease. Kidney Int. 97, 261\u2013263 (2020).","journal-title":"Kidney Int."},{"key":"24104_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1681\/ASN.2008050507","volume":"20","author":"Y Pei","year":"2009","unstructured":"Pei, Y. et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J. Am. Soc. Nephrol. 20, 205\u2013212 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"24104_CR21","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1681\/ASN.2014030297","volume":"26","author":"Y Pei","year":"2015","unstructured":"Pei, Y. et al. Imaging-based diagnosis of autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 26, 746\u2013753 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"24104_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604\u2013612 (2009).","journal-title":"Ann. Intern. Med."},{"key":"24104_CR23","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1681\/ASN.2011101032","volume":"23","author":"S Rossetti","year":"2012","unstructured":"Rossetti, S. et al. Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J. Am. Soc. Nephrol. 23, 915\u2013933 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"24104_CR24","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/ki.2008.485","volume":"74","author":"MB Consugar","year":"2008","unstructured":"Consugar, M. B. et al. Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1\/TSC2 contiguous gene syndrome. Kidney Int. 74, 1468\u20131479 (2008).","journal-title":"Kidney Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24104-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24104-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24104-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T07:05:27Z","timestamp":1676876727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24104-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["24104"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-24104-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1537178\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"assertion":[{"value":"8 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MBL has received compensation for participation as a speaker and an advisory board member with Otsuka, Reata, Bayer, and Sanofi-Genzyme Pharmaceuticals. YP has received compensation for participation in advisory boards for Otsuka, Sanofi-Genzyme, and Reata Pharmaceuticals. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2952"}}